CytomX Therapeutics Stock Forecast, Price & News

+0.08 (+1.12 %)
(As of 06/14/2021 04:46 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume572,074 shs
Average Volume996,364 shs
Market Capitalization$470.68 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CytomX Therapeutics logo

About CytomX Therapeutics

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

520th out of 2,100 stocks

Pharmaceutical Preparations Industry

251st out of 831 stocks

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

Is CytomX Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CytomX Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View analyst ratings for CytomX Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CytomX Therapeutics?

Wall Street analysts have given CytomX Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CytomX Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for CytomX Therapeutics

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.26) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.03. CytomX Therapeutics had a negative net margin of 90.87% and a negative trailing twelve-month return on equity of 80.13%.
View CytomX Therapeutics' earnings history

How has CytomX Therapeutics' stock been impacted by Coronavirus (COVID-19)?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CTMX stock has increased by 23.3% and is now trading at $7.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CTMX?

5 analysts have issued 12 month target prices for CytomX Therapeutics' shares. Their forecasts range from $7.00 to $14.00. On average, they anticipate CytomX Therapeutics' stock price to reach $10.38 in the next year. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for CytomX Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 54, Pay $907.75k)
  • Mr. Frederick W. Gluck, Co-Founder & Independent Director (Age 86, Pay $49.38k)
  • Mr. Lloyd A. Rowland Jr., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 64, Pay $574.06k)
  • Dr. Amy C. Peterson M.D., Exec. VP & Chief Devel. Officer (Age 54, Pay $2.17M)
  • Mr. Carlos Campoy, Sr. VP & CFO (Age 56)
  • Dr. Chau Cheng M.B.A., Ph.D., VP of Investor Relations & Corp. Communications
  • Dr. Sridhar Viswanathan Ph.D., Sr. VP of Process Sciences & Manufacturing Operations
  • Ms. Danielle Olander, Sr. VP, Talent & Systems Devel.
  • Ms. Alison Joly, Sr. VP of Program & Alliance Management
  • Ms. Leslie Robbins, Sr. VP of Intellectual Property

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (9.74%), BlackRock Inc. (7.98%), RA Capital Management L.P. (5.38%), Victory Capital Management Inc. (4.26%), Perceptive Advisors LLC (3.31%) and Price T Rowe Associates Inc. MD (2.61%).
View institutional ownership trends for CytomX Therapeutics

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Perceptive Advisors LLC, D. E. Shaw & Co. Inc., Morgan Stanley, Man Group plc, Panagora Asset Management Inc., Credit Suisse AG, and Thrivent Financial for Lutherans.
View insider buying and selling activity for CytomX Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., RA Capital Management L.P., BlackRock Inc., Price T Rowe Associates Inc. MD, Platinum Investment Management Ltd., Victory Capital Management Inc., Geode Capital Management LLC, and Janus Henderson Group PLC.
View insider buying and selling activity for CytomX Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $7.24.

How much money does CytomX Therapeutics make?

CytomX Therapeutics has a market capitalization of $470.68 million and generates $100.36 million in revenue each year. The biotechnology company earns $-32,880,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

CytomX Therapeutics employs 144 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is

Where are CytomX Therapeutics' headquarters?

CytomX Therapeutics is headquartered at 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.